Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335374 · ClinicalTrials.gov registry record · Phase 3
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT00335374: Completed Phase 3 study, sponsored by Solvay Pharmaceuticals.
NCT00335374 is a Phase 3 study that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 202 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00335374, a Phase 3 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial
Interventions
- DRUG Pardoprunox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
What the finished NCT00335374 record still lists
NCT00335374 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Pardoprunox is the first listed.
NCT00335374 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00335374 about?
NCT00335374 is a clinical study titled "An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients". This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial
What is the current status of trial NCT00335374?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2007-08. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00335374?
The interventions under investigation include: Pardoprunox (DRUG).
Who is sponsoring clinical trial NCT00335374?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00335374's enrollment target sits among peer trials
202 1353rd of 2000 higher than 648 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia